Beckman Agreement Will Give Biosite Automated Platform For BNP Assay
This article was originally published in The Gray Sheet
Executive Summary
Biosite will leverage Beckman Coulter's U.S. installed base of automated immunoassay analyzers to grow its market share in BNP testing under a long-term development deal between the firms
You may also be interested in...
Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion
In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite
Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion
In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite
BioSite Launches Triage Stroke Panel In Europe, Defends BNP Test Share
BioSite's European launch of its Triage stroke panel comes as the firm faces increasing BNP test pricing pressure from Abbott Labs